Bob Azelby, Eliem Therapeutics CEO
July 18, 2022 10:32 AM EDT
R&D

Eliem de­lays a de­pres­sion tri­al, in­def­i­nite­ly post­pones an­oth­er af­ter blam­ing CMC is­sues for low drug ex­po­sure

Kyle LaHucik

Senior Reporter

In the drug R&D world, plans are not set in stone, as Eliem Ther­a­peu­tics ex­hib­it­ed Mon­day with shifts to its de­pres­sion strat­e­gy.

The Seat­tle-UK biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times